Bryon D. Johnson, PhD

Professor, Pediatrics (Hematology/Oncology/BMT) and Microbiology & Immunology

Locations

Microbiology & Immunology

Contact Information

General Interests

Cancer immunology and immunotherapy

Education

PhD, Immunology, University of Health Sciences/The Chicago Medical School (now Rosalind Franklin University), 1989
BS, Microbiology, Iowa State University, 1983

Research Interests

I am interested in understanding the biology and immunology of cancer, and uncovering novel immune-based approaches to treat cancer. My current research focuses on combining the following approaches to improve the use of cancer immunotherapy for treating both solid tumors and hematologic cancers: (1) immune checkpoint protein blockade, (2) adoptive transfer of cancer-reactive T lymphocytes, and (3) the use of metabolic inhibitors to increase T cell immunity.

An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.

(Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A.) J Clin Apher. 2019 Dec;34(6):686-691 PMID: 31566813 PMCID: PMC6957224 SCOPUS ID: 2-s2.0-85073930913 10/01/2019
Bone Marrow-derived CD8+ T Cells From Pediatric Leukemia Patients Express PD1 and Expand Ex Vivo Following Induction Chemotherapy.

(Palen K, Thakar M, Johnson BD, Gershan JA.) J Pediatr Hematol Oncol. 2019 Nov;41(8):648-652 PMID: 29912035 PMCID: PMC6855330 SCOPUS ID: 2-s2.0-85048631854 06/19/2018
Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice.

(Jing W, Chen J, Cai Y, Chen Y, Schroeder JA, Johnson BD, Cui W, Shi Q.) Blood Adv. 2019 Oct 22;3(20):3099-3110 PMID: 31648333 PMCID: PMC6849959 SCOPUS ID: 2-s2.0-85074935557 10/28/2019
A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.

(D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A.) Biol Blood Marrow Transplant. 2019 08;25(8):1492-1497 PMID: 30959163 SCOPUS ID: 2-s2.0-85065451525 04/09/2019
STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.

(Jing W, McAllister D, Vonderhaar EP, Palen K, Riese MJ, Gershan J, Johnson BD, Dwinell MB.) J Immunother Cancer. 2019 04 29;7(1):115 PMID: 31036082 PMCID: PMC6489306 SCOPUS ID: 2-s2.0-85065258266 05/01/2019
A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Metastasis.

(Tsai S, McOlash L, Jia S, Zhang J, Simpson P, Kaldunski ML, Aldakkak M, Grewal J, Palen K, Dwinell MB, Johnson BD, Mackinnon A, Hessner MJ, Gershan JA.) Cancer Epidemiol Biomarkers Prev. 2019 04;28(4):680-689 PMID: 30530849 PMCID: PMC6545232 SCOPUS ID: 2-s2.0-85063867816 12/12/2018
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies.

(Shah NN, Maatman T, Hari P, Johnson B.) Front Oncol. 2019;9:146 PMID: 30915277 PMCID: PMC6423158 SCOPUS ID: 2-s2.0-85063343499 03/28/2019
Frontline Science: PECAM-1 (CD31) expression in naïve and memory, but not acutely activated, CD8 T cells.

(Newman DK, Fu G, McOlash L, Schauder D, Newman PJ, Cui W, Rao S, Johnson BD, Gershan JA, Riese MJ.) J Leukoc Biol. 2018 11;104(5):883-893 PMID: 30063264 PMCID: PMC6195461 SCOPUS ID: 2-s2.0-85053248137 08/01/2018
Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance.

(Wesley EM, Xin G, McAllister D, Malarkannan S, Newman DK, Dwinell MB, Cui W, Johnson BD, Riese MJ.) Immunohorizons. 2018 Apr 01;2(4):107-118 PMID: 30027154 PMCID: PMC6048965 07/22/2018
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft--host disease: low incidence of lower gastrointestinal tract disease.

(Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M.) Haematologica. 2018 04;103(4):717-727 PMID: 29351985 PMCID: PMC5865423 SCOPUS ID: 2-s2.0-85044420638 01/21/2018
Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.

(Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA.) BMC Cancer. 2018 03 27;18(1):335 PMID: 29587663 PMCID: PMC5870823 SCOPUS ID: 2-s2.0-85044523365 03/29/2018
Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator

(Pan J, Zhang Q, Palen K, Wang L, Qiao L, Johnson B, Sei S, Shoemaker RH, Lubet RA, Wang Y, You M.) EBioMedicine. 2019 SCOPUS ID: 2-s2.0-85074132937 01/01/2019

Bryon D. Johnson, PhD